Mesothelioma - Pipeline Insight, 2025

This “Mesothelioma - Pipeline Insight, 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Mesothelioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Mesothelioma: Understanding

Mesothelioma: Overview

Mesothelioma is a rare and aggressive cancer linked to asbestos exposure, particularly the amosite and crocidolite types. It primarily affects the pleura (lining of the lungs) but can also develop in the peritoneum and pericardium. With a long latency period, the disease is more common in individuals exposed to asbestos in high-risk industries like shipbuilding. Although the overall incidence has declined with better regulations, mesothelioma remains prevalent in areas with past asbestos exposure. Men are more frequently diagnosed than women, and many patients are diagnosed at advanced stages, often when the disease is harder to treat.

Malignant mesothelioma is primarily linked to asbestos exposure, which is believed to cause repeated inflammation, interference with cell division, activation of proto-oncogenes, and free radical production. Other contributing factors include ionizing radiation (such as mantle radiation for Hodgkin lymphoma) and genetic mutations, particularly in the BRCA 1 Associated Protein (BAP1) gene. While smoking does not directly cause mesothelioma, it significantly increases the risk of lung cancer when combined with asbestos exposure. High-risk occupations include shipbuilding, mining, ceramics, cement manufacturing with asbestos, auto parts manufacturing (especially brake lining), paper mills, insulation work, and railroad repair. Genetic factors, including chromosomal anomalies such as the loss of chromosome 22, may increase susceptibility to the disease. There is no evidence linking alcohol, tobacco, or dietary intake to mesothelioma.

Malignant mesothelioma is classified into three histological types: epithelioid, sarcomatoid, and mixed, with the epithelioid type generally associated with better outcomes. The tumor often begins as multiple nodules on the parietal pleura, spreading locally to the visceral pleura, and may extend to the chest wall, diaphragm, or mediastinum. Lymph node involvement follows a distinct pattern compared to lung cancer, with metastasis typically occurring through direct local invasion to the bronchopulmonary or hilar nodes, followed by the carinal, internal mammary, or peridiaphragmatic nodes. Lymph node involvement is relatively uncommon in malignant pleural mesothelioma, and spread tends to be local rather than distant.

The treatment of mesothelioma involves surgery, chemotherapy, radiotherapy, and palliative care. Surgery is recommended for medically fit patients, while chemotherapy with cisplatin and pemetrexed is the standard treatment for most cases. Palliative care options, such as talc pleurodesis for pleural effusions and radiotherapy for symptom management, help improve quality of life. New treatments, like photodynamic therapy, are being explored, but the focus remains on symptom control and disease management. Multidisciplinary teams are crucial in developing individualized treatment plans based on the patient's overall health and disease stage. Despite advances in treatment, the prognosis remains poor, and ongoing research aims to find more effective therapies. Supportive care is essential for managing symptoms and improving the patient's quality of life.

'Mesothelioma- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mesothelioma pipeline landscape is provided which includes the disease overview and Mesothelioma treatment guidelines. The assessment part of the report embraces, in depth Mesothelioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mesothelioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Mesothelioma R&D. The therapies under development are focused on novel approaches to treat/improve Mesothelioma.

Mesothelioma Emerging Drugs Chapters

This segment of the Mesothelioma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Mesothelioma Emerging Drugs

Pegargiminase: Polaris Pharmaceuticals

Pegargiminase (ADI‑PEG 20), is a biologic in late-stage clinical development for a wide range of cancers. It is a novel therapeutic protein being developed for cancers with a unique metabolic trait. Pegargiminase deprives the cancer cells of the amino acid Arginine by converting plasma-borne arginine into citrulline. At the core of their deficiency is a down-regulation of Argininosuccinate Synthase (ASS1), an enzyme needed to synthesize arginine. To survive, the cancer cells must “rewire” their metabolism. This exerts a stress on the cells that renders them more susceptible to conventional chemotherapies. Pegargiminase has also gained Orphan Drug Designation for mesothelioma both in the U.S. and in Europe. Currently, the drug is in Preregistration stage of its development for the treatment of Mesothelioma.

Volrustomig: AstraZeneca

Volrustomig is an engineered Fragment Crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, volrustomig targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Mesothelioma.

Tremelimumab: MedImmune LLC

Tremelimumab is a type of monoclonal antibody and a type of immune checkpoint inhibitor. It is a drug that binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat different types of cancer. Tremelimumab is directed against cytotoxic T- lymphocyte-associated protein 4 (CTLA-4). By blocking the activity of CTLA-4, tremelimumab “releases the brakes” on T cell activation and boosts the immune response against cancer cells. It is a fully human monoclonal antibody, which stimulates the immune system to destroy cancer cells through binding to the protein CTLA-4, expressed on the surface of activated T-lymphocytes. Tremelimumab has been granted Orphan Drug Designation and Fast Track Designation form the US Food and Drug Administration. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Mesothelioma.

TAK-500: Takeda

TAK-500 is a first-in-class STING agonist immunostimulatory antibody drug conjugate (iADC) that delivers dazostinag to CCR2+ myeloid cells in the tumor microenvironment. By targeting the STING pathway and CCR2 expressing myeloid cells, TAK-500 may offer enhanced potency via improved PK and selective delivery. TAK-500 has three possible mechanisms of action: activation of IFN response, reprogramming of suppressive intratumoral CCR2+ myeloid cells, and blockade of suppressive tumor-associated macrophage recruitment. Activation of STING leads to the production of proinflammatory cytokines that activate dendritic cells, macrophages, and natural killer cells, and subsequently mobilize adaptive immune cells against tumor cells. Combining TAK-500 with radiation and/or checkpoint inhibitors led to enhanced antitumor activity in preclinical studies. Dying tumor cells release tumor antigens and tumor-derived cGAMP, which continue to activate the STING pathway. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Mesothelioma.

RSO-021: RS Oncology LLC

RSO-021 is a naturally occurring, sulfur-rich, cyclic oligopeptide of the thiopeptide class, which covalently inactivates PRX3, leading to catastrophic oxidative stress and cell death. It is a novel first-in-class small molecule that irreversibly binds and inhibits mitochondrial peroxiredoxin 3 (PRX3). Inhibition of the PRX3 antioxidant signaling network in mitochondria results in selective killing of malignant cells by upregulation of oxidative stress; in contrast, healthy tissue is spared. In pre-clinical models RSO-021 reduces tumor growth in mice, sensitizes tumor cells to apoptosis and reduces the expression of pro-metastatic epithelial to mesenchymal (EMT) genes. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Mesothelioma.

Mesothelioma: Therapeutic Assessment

This segment of the report provides insights about the different Mesothelioma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Mesothelioma

• There are approx. 45+ key companies which are developing the therapies for Mesothelioma. The companies which have their Mesothelioma drug candidates in the most advanced stage, i.e. Preregistration include, Polaris Pharmaceuticals.

Phases

The report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Mesothelioma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Mesothelioma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mesothelioma drugs.

Mesothelioma Report Insights

• Mesothelioma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Mesothelioma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Mesothelioma drugs?
• How many Mesothelioma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mesothelioma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Mesothelioma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Mesothelioma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Polaris Pharmaceuticals
• AstraZeneca
• MedImmune LLC
• Takeda
• RS Oncology LLC
• Vivace Therapeutics, Inc
• VM Oncology, LLC
• KaliVir Immunotherapeutics
• UTC Therapeutics Inc.

Tango Therapeutics, Inc.

Verismo Therapeutics

• SpringWorks Therapeutics, Inc.

Gilead Sciences

• Nurix Therapeutics, Inc.

Amphera BV

• Merck Sharp & Dohme LLC
• Constellation Pharmaceuticals
• BridGene Biosciences Inc.

Aromics Therapeutics

• Ascentage Pharma Group Inc.

7 Hills Pharma, LLC

Key Products

• Pegargiminase
• Volrustomig
• Tremelimumab
• TAK-500
• RSO-021
• VT3989
• VMD-928
• VET3-TG
• UCMYM802 Injection
• TNG908
• SynKIR-110
• SW-682
• Sacituzumab
• NX-1607
• MesoPher
• Lenvatinib
• CPI-0209
• BGC515
• AROG4-01
• APG-2449
• Alintegimod

This product will be delivered within 1-3 business days.